Topp, P. D. M. S., Wang, G., Patel, P., Yusuf, R., Lavie, D. (2025). Zilovertamab vedotin plus R-CHP versus polatuzumab vedotin plus R-CHP as first-line therapy in participants with germinal center B-cell diffuse large B-cell lymphoma (DLBCL): The randomized, open-label, Phase 2 waveline-011 Study. Blood. https://doi.org/10.1182/blood-2025-5480